GlobeNewsWire
05 Jul 2026, 15:49 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
GeneDx cut its 2026 revenue guidance from $540–$555 million down to $475–$490 million. — A significant downward revision of annual guidance typically triggers a sharp decline in valuation and investor confidence.
-0.80GeneDx reported a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition, which was purchased for $36.5 million only a year prior. — Writing off nearly the entire value of a recent acquisition indicates a severe failure in strategic execution or overpayment.
-0.70GeneDx's average reimbursement rate was $3,300, which was $200 below expectations. — Lower-than-expected reimbursement rates directly compress margins and suggest a weakening of the company's pricing power.
-0.50Continue reading
6 related stories
Top 3 movers · tap to explore
GeneDx is facing a federal securities class action lawsuit alleging false and misleading statements regarding margins and the Fabric Genomics acquisition. — Legal proceedings introduce additional financial liability and regulatory risk, though the impact is often secondary to the operational failures that caused the suit.
-0.40Which stocks this story touches
The company is facing a federal securities class action lawsuit following a 49% stock price crash, missed earnings, lowered guidance, and a significant goodwill impairment charge.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
